Samsung fund invests in US gene therapy firm


SEOUL: Samsung Life Science Fund, an investment fund created by Samsung affiliates, will invest in Latus Bio, a US gene therapy development company, according to Samsung Bioepis.

It is the sixth investment made by the fund between Samsung Biologics, Samsung C&T and Samsung Bioepis, to explore new business opportunities in the biotechnology sector. The exact amount of investment has not been disclosed.

Get 20% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Samsung , investment , gene , technology

Next In Business News

Farm Fresh posts net profit of RM26.82mil in 1Q amid elevated costs
Malaysia's international reserve assets at US$132.07bil as of end-July
Malaysia's PPI rises 9.7% in July 2026
ASM 2 Wawasan declares income distribution amounting to RM1.31bil, highest in 7 years
Malaysia's export unit value index up 0.6% in July 2026 -- DOSM
CIMB's 2Q net profit rises to RM1.94bil, declares 19.65c div/share
Hibiscus Petroleum registers net profit of RM361.27mil in FY26
RHB Bank's net profit rises to RM1.66bil in 1H, declares 15c div/share
Mah Sing achieves RM1.32bil sales in 1H, net profit rises to RM140.55mil
Australian dollar extends winning streak to ninth week as rate outlook shifts

Others Also Read